Mar 31, 2020
New Retrospective Two-Year Study Demonstrates Velphoro® Effectiveness
Nov 06, 2019
Fresenius Medical Care North America Presents New Insights for Kidney Care at the American Society of Nephrology (ASN) Annual Kidney Week
Sep 03, 2019
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Jun 25, 2019
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia's Auryxia, Amgen's Parsabiv, and Opko's Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
Mar 07, 2019
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Jan 28, 2019
Velphoro® Doubles Percentage of Patients Reaching Target Serum Phosphorous Levels in New Study Published in Journal of Renal Nutrition
Oct 26, 2018
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Jul 24, 2018
Amgen's Parsabiv Doubles in Most Recent Quarter But Strict Usage Guidelines from Large Dialysis Organizations, DaVita and Fresenius Medical Care, Stifle Potential
Nov 14, 2017
In the CKD-MBD Market, OPKO's Rayaldee Continues to Struggle While Keryx's Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights
Aug 10, 2017
Changes Afoot in the Management of CKD Mineral Bone Disorder Reinforced by a Clinical Practice Guideline Update from KDIGO